Company Presentation August 2017

Transcription

1 Company Presentation August 2017

2 Legal Disclaimer IMPORTANT NOTICE This presentation has been prepared by OrthoSpin Ltd. (the Company ) solely for informational purposes. The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be complete or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any errors omissions in, this presentation. This presentation includes certain statements and estimates provided by the Company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. This presentation may contain statements that are not historical facts, referred to as forward looking statements. The Company s actual future results may differ materially from those suggested by such statements. No assurance can be given that future events will occur or that projections will be achieved. Past performance is not a reliable indication of future performance. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company s securities, or an offer to sell, or a solicitation of an offer to buy, the Company s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. Prospective investors should not construe the contents of this presentation as business, legal, tax, investment or other advice. Each prospective investor should make his, her or its own inquiries and consult his, her or its own advisors as to the appropriateness and desirability of an investment in the Company and as to business, legal, tax and related matters concerning an investment in the Company. An investment in the Company shall be allowed only to such number and category of investors in accordance with applicable laws and regulations and pursuant to a predetermined process. Accordingly, detailed information in connection with the investment shall be revealed and delivered only to a limited number of qualifying investors as provided by law.

3 Overview Orthospin is developing a smart external fixation system for the orthopedic trauma market FIM Q FDA/CE submissions Q Investors: The Trendlines Group The company is looking for funding to finance its activities until commercialization

4 External Fixation: First Line of Treatment Complex bone injuries Bone lengthening Limb deformities Hexapod-shaped external frame stabilizes broken bones until healing occurs.

5 Success Relies on Daily Manual Adjustments knob Image: OrthoFix International 6 adjustable knobs are turned manually every day

6 Success Relies on Patient Commitment Sample adjustment schedule the patient must follow turning 6 struts approximately 1 mm each day. The knob is part of the strut (or rod).

7 Manual Adjustment Is Problematic

8 Doctors Are Left Out! Physician lacks precise feedback as to patient progress. Lack of information results in improper healing and prolonged treatment.

9 The Future of External Fixation

10 Part of the Digital Health Care Revolution

11 A Win for Physician, Patient & Hospital Real-time feedback Less complication and injuries to soft tissue Improved clinical results Optimizing patient follow-up schedule Full compliance Accurate adjustments Improved clinical results Reduced revision surgeries Less pain Reduced costs Reduced revision surgeries Reduce treatment time Increased patient eligibility for treatment

12 OrthoSpin Market Opportunity ~ US$450 million globally (devices that require adjustable struts primarily circular and hexapod fixation devices) 7% CAGR by 2020 Asia: fastest growth due to aging population and improved trauma surgery centers 12

13 Major Players Are Active 13

14 IP: Preloaded Medical Strut PCT_WO A1 Issue date: 12-March-2015 Register to: USA, Europe and China Status: National Phase registration applies to hexapod, monorail, internal nail

15 IP: User Interface for Strut Device Issue date: 19-June-2016 Status: Provisional applies to external fixation, internal fixation, internal nail

16 Regulation and Reimbursement FDA 510K Class II Predicate: Autogenesis is 510k, class II CE Class IIa, possible Class IIb Hogan Lovells :No human clinical trials required Reimbursement in place

17 Strong Management Team Oren Cohen, CEO: More than 10 years experience with medical devices and communications companies; previously, senior positions at Neuronix, Medtronic, Spectrum Dynamics, Karmel Sonics, Qualcomm, Primesense Assaf Dekel, MD, Active Director: a practicing orthopedic surgeon with more than 13 years of experience in the medical device industry. Dr. Dekel founded Orthospace and Neatstitchand has also played a leading role in various early stage companies. Dr. Dekel holds an M.D. from the Hebrew University in Jerusalem Yoni Epstein, Co-Founder: Co-founder and CEO, Anchora Medical; former co-founder and CEO, InnoLap Surgical, acquired by Teleflex (NYSE: TFX); General Manager of Emergency Medicine business unit, Deep Breeze; Marketing Director Liraz Shlomoff, Co-Founder: CEO, Trimaco Surgical, major Israeli orthopedic device distributor; partner, Carevature, development of smart tools and procedures for orthopedic surgery

18 Scientific Advisory Board John E. Herzenberg, MD: Director of Pediatric Orthopedics at Sinai Hospital and Director of the ICLL; Dr. Herzenberg trained in limb lengthening directly with Professor Ilizarov in the USSR. Scott Nelson, MD: Assistant Professor of Orthopedic Surgery, Loma Linda University. Eitan Segev, M.D.; Director, Orthopedic Dep t., Sourasky (Ichillov),Medical Center, Israel Haim Shtarker, M.D.; Director, Orthopedic Dep t., Galilee Medical Center, Israel

19 Getting Ready for Market Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FIM FDA Israel CE Submissions FIH US FDA CE Approvals

20 Financing Round Use of proceeds: FDA/CE approval Clinical trials in Israel and the US Product optimization for commercialization Additional patent

21 Why Orthospin? Strong team and advisory board Quick to market: compatible with existing frames; maintain same supplier Orthopedic players seek innovation; no change in the last 15 years Strong IP

22 Why Orthospin? Cost-saving system Simple regulation Pricing similar to existing manual frames Orthospin system is a platform, for example bone Magnetic Stimulation (Bayonet and Orthofix) Clear and short-term path to market

23 Oren Cohen, CEO